ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase I drugs for Peripheral T-Cell Lymphomas (PTCL) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ICG-122’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ICG-122 overview
Gene therapy is under development for the treatment of CD4 positive leukemias including peripheral T-cell leukemias, T-cell prolymphocytic leukemia, adult T-cell leukemia, T-cell large granular lymphocytic leukemia and T cell acute lymphoblastic leukemia T-ALL and CD4 positive lymphomas including peripheral T-cell lymphoma, sezary syndrome, cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma adult T-cell lymphoma, relapsed and refractory acute myeloid leukemia and chronic myelomonocytic leukemia. The therapy comprises of T cells genetically modified by lentiviral transduction to express a chimeric antigen receptor (CAR) targeting the antigen CD4. It was also under development for the treatment of acute myeloid leukemia and relapsed or refractory multiple myeloma.
ICell Gene Therapeutics overview
iCell Gene Therapeutics (ICell Gene) is a biotechnology company. The company research and develops chimeric antigen receptor engineered cells that target multiple types of cancer with poor prognoses. It offers CARvac, T-cell targeted, compound CAR’s and universal CAR’s. ICell Gene offers orphan drug designation for five CARs in multiple myeloma, peripheral t-cell lymphoma, acute myeloid leukemia, b-acute lymphocytic leukemia and t-cell acute lymphocytic leukemia. The company creates novel CAR constructs and CAR enhancing technologies for applicability of transduced T and NK cells. It has operations in the US and China. ICell Gene is headquartered in Brookhaven, New York, the US.
For a complete picture of ICG-122’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
